68Ga-DOTA-NOC: A new PET tracer for evaluating patients with bronchial carcinoid

Nuclear Medicine Communications

Volumn 30, Issue 4, 2009, Pages 281-286

  Ambrosini, Valentina ^a   Castellucci, Paolo ^a   Rubello, Domenico ^b   Nanni, Cristina ^a   Musto, Alessandra ^a   Allegri, Vincenzo ^a   Montini, Gian Carlo ^a   Mattioli, Sandro ^a   Grassetto, Gaia ^b   Al Nahhas, Adil ^c   Franchi, Roberto ^a   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b 'Santa Maria della Misericordia' Hospital   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

68Ga DOTA NOC; Neuroendocrine tumours; PET computed tomography, somatostatin receptors

Indexed keywords

(1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID) 3 (1 NAPHTHALENYL)ALANYLOCTREOTIDE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; GALLIUM 68; OCTREOTIDE; PENTETREOTIDE IN 111; UNCLASSIFIED DRUG; 68GA TETRAAZACYCLODODECANE TETRAACETIC ACID NAL(3) OCTREOTIDE; 68GA-TETRAAZACYCLODODECANE TETRAACETIC ACID-NAL(3)-OCTREOTIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM 111 OCTREOTIDE; INDIUM-111-OCTREOTIDE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BRONCHUS CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LIVER LOBECTOMY; LUNG LOBE; MALE; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE DISTRIBUTION; TUMOR LOCALIZATION; WHOLE BODY SCINTISCANNING; AUTORADIOGRAPHY; BRONCHUS TUMOR; CARCINOID; COMPUTER ASSISTED EMISSION TOMOGRAPHY; IMAGE PROCESSING; METASTASIS; MIDDLE AGED; SCINTISCANNING;

AGED; AGED, 80 AND OVER; AUTORADIOGRAPHY; BRONCHIAL NEOPLASMS; CARCINOID TUMOR; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 63149183207     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32832999c1     Document Type: Article

References (44)

1. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128:1717-1751.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13 715 carcinoid tumors. Cancer 2003; 97:934-959.
3. Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C, Faivre J. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 2004; 53:549-553.
4. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004; 80 (Suppl 1):3-7.
5. Gustafsson Bl, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol 2008; 20:1-12.
6. Jiang SX, Kameya T, Shoji M, Dobashi Y, Shinada J, Yoshimura H. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Am J Surg Pathol 1998; 22:526-537.
7. McCaughan BC, Martini N, Bains MS. Bronchial carcinoids. Review of 124 cases. J Thorac Cardiovasc Surg 1985; 89:8-17.
8. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 1972; 64:413-421.
9. McMullan DM, Wood DE. Pulmonary carcinoid tumors. Semin Thorac Cardiovasc Surg 2003; 15:289-300.
10. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998; 22:934-944.
11. Skuladottir H, Hirsch FR, Hansen HH, Olsen JH. Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002; 37:127-135.
12. Harpole DH Jr, Feldman JM, Buchanan S, Young WG, Wolfe WG. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg 1992; 54:50-54; discussion 54-55.
13. Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazeer M, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001; 119:1647-1651.
14. Torre M, Barberis M, Barbieri B, Bonacina E, Belloni P. Typical and atypical bronchial carcinoids. Respir Med 1989; 83:305-308.
15. Marty-Ane CH, Costes V, Pujol JL, Alauzen M, Baldet P, Mary H. Carcinoid tumors of the lung: do atypical features require aggressive management? Ann Thorac Surg 1995; 59:78-83.
16. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med 1998; 25:79-83.
17. Brandt B III, Heintz SE, Rose EF, Ehrenhaft JL. Bronchial carcinoid tumors. Ann Thorac Surg 1984; 38:63-65.
18. Beasley MB, Thunnissen FB, Brambilla E, Hasleton P, Steele R, Hammar SP, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000; 31:1255-1265.
19. Filosso PL, Rena O, Donati G, Casadio C, Ruffini E, Papalia E et al. Bronchial carcinoid tumors: surgical management and long-term outcome. J Thorac Cardiovasc Surg 2002; 123:303-309.
20. 18Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35:1431 -1438.
21. 68Ga-DOTA-NOC PET. Biomed Pharmacother 2008; 62:667-671.
22. Solcia E, Kloppel G, Sobin LH, Capella C, Delellis RA, Heitz PU, et al., editors, Histological typing of endocrine tumours. 2nd ed. Heidelberg: Springer; 2000.
23. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004; 31:1097-1104.
24. 68Ga for medical application. J Nucl Med 2007; 48:1741-1748.
25. Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003; 30:1338-1347.
26. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogaltium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007; 34:982-993.
27. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. (68)Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008; 35:72-79.
28. Bunyaviroch T, Coleman RE. PET evaluation of lung cancer. J Nucl Med 2006; 47:451-469.
29. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. UKNET work for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Guf 2005; 54 (Suppl 4):iv1 -iv16.
30. Wartski M, Alberini JL, Leroy-Ladurie F, De Montpreville V, Nguyen C, Corone C, et al. Typical and atypical bronchopulmonary carcinoid tumors on FDG PET/CT imaging. Clin Nucl Med 2004; 29:752-753.
31. Patz EF, Lowe VJ, Hoffman JM. Focal pulmonary abnormalities: evaluation with F-I8 fluorodeoxyglucose PET scanning. Radiology 1993; 188:487-490.
32. Lowe VI, Duhaylongsod FG, Pals EF. Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology 1997; 202:435-439.
33. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Chest 1993; 104:997-1002.
34. Gupta NC, Frank AR, Dewan NA, Redepenning LS, Rothberg ML, Mailliard JA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18-fluoro-2-deoxy-D-glucose. Radiology 1992; 184:441-444.
35. Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH, Hor G. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun 1998; 19:641-647.
36. Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998; 170:1369-1373.
37. Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR.The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 2007; 131:255-260.
38. Chong S, Lee KS, Kim BT, Choi JY, Yi CA, Chung MJ, et al. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol 2007; 188:1223-1231.
39. 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006; 129:393-401.
40. 111In-pentetreotide negative GEP tumours. Nucl Med Commun 2007; 28:473-477.
41. 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006; 33:460-466.
42. Waldherr C, Pless M, Maecke HR, Schumacher T Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002; 43:610-616.
43. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48:508-518.
44. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003; 30:781 -793.